Case Report {#sec1-1}
===========

A 2-day-old male infant presented with central and peripheral cyanosis. No others signs of respiratory distress or hypoxia were observed and pulseoxymetry test showed a saturation of 86-90% at room air.

Infant was born through spontaneous vaginal delivery to 28-year-old woman (gravida 2 para 2, GA 40 wk), who received routine prenatal care and screening. Apgar scores at birth were 10/10 at 1 and 5 minutes, respectively. According to mother, infant was feeding regularly and she did not notice any abnormalities in his behavior. Her firstborn child is healthy and asymptomatic.

Complete blood count revealed hematocrit (Hct) of 0.85% (reference range 0.45-0.72) and hemoglobin of 289 g/L (reference range 145-220).^[@ref1]^ C reactive protein, procalcitonin, blood gases (capillary) were within normal ranges, no abnormalities were found on chest x-ray, neurosonography and echocardiography. Methemoglobin (MetHb) level was normal 2.6% (\<3%).

Non-invasive respiratory support with continuous positive airway pressure and supplemental oxygen was started but had no effect on saturation or cyanosis. After blood work and diagnostic testing, intravenous glucose was started as treatment for polycythemia. Cyanosis and low saturation remained even with improvement of Hct after intravenous glucose infusion. Methemoglobinemia was not considered due to low apparent MetHb concentration (ABL90 FLEX analyzer). Lack of inflammatory markers and narrow nature of clinical presentation made early onset of infection unlikely. Neither clinical presentation, respiratory support or oxygen supply, nor changes on chest x-ray confirmed respiratory distress syndrome. Mothers' blue fingers and lips were noticed by clinician ([Figure 1](#fig001){ref-type="fig"}). Additional questioning revealed that some of 2^nd^, 3^rd^, 4^th^ degree relatives possess persistent blueish discoloration of the lips and fingertips. There were no consanguineous marriages in family's history and both parents were of European descent. Neither mother, nor relatives have complaints or associated symptoms with aforementioned discoloration.

As there was high suspicion (atypical phenotype in mother and relatives) of possible hereditary methemoglobinemia, additional tests were performed. Control analyte test was performed with blood being drawn from the patient, patient's mother and two healthy control samples for MetHb content analysis and sent to central laboratory for analysis. Color difference in patients' and his mothers' blood samples was also distinctively noticeable compared to healthy controls ([Figure 2](#fig002){ref-type="fig"}). Results from central laboratory (using ABL800 BASIC analyzer) revealed increased MetHb in the mother (14.8%) as well as the infant (4.0%) confirming congenital methemoglobinemia ([Table 1](#table001){ref-type="table"}). Previous treatments were suspended, no specific treatment for methemoglobinemia was applied due to low concentration of MetHb. Patient was discharged in a stable condition with mild, barely noticeable cyanosis only while crying. Hemoglobin electrophoresis obtained later was unremarkable. Cytochrome B^5^ reductase (CYB^5^R) activity level, sequence analysis of the β and γ globin genes were not obtained, due to limited availability in the region. No developmental delay or growth retardation was observed (head circumference between 25-50 centile, weight and height between 50-75 centiles) at 6 months of age.

Discussion {#sec1-2}
==========

Congenital methemoglobinemia is a very rare cause of childhood cyanosis. Pathogenesis is best described by the increased and sustained concentration of oxidized hemes. This results in inability of hemoglobin to bind and carry oxygen shifting oxygen dissociation curve to the left, thus compromising oxygen supply to the tissues. Under normal conditions MetHb levels are kept under 1%.^[@ref2]^ Methemoglobinemia can be acquired (caused by various oxidizing agents) or genetic (caused by deficiency of CYB^[@ref5]^R or cytochrome B^5^ systems). Acquired is usually attained by nitrite ingestion or exposure to certain medications (anesthetics being most frequent).^[@ref2]^ Symptoms of methemoglobinemia are associated with hypoxemia (produced by inefficient gas exchange) which directly correlates with MetHb plasma levels^[@ref3]^ ([Table 2](#table002){ref-type="table"}).

Congenital methemoglobinemia is categorized into two forms: type I (more common) and type II (rare and severe). Type I is characterized by CYB^5^R functional deficiency in red blood cells. This type of disorder results in MetHb concentrations up to 40%,^[@ref2]^ although most patients adapt to increased MetHb levels by compensatory polycythemia and have little to no symptoms unless exposed to oxidizing agents.^[@ref4]^ This form is distributed worldwide, although endemic zones exist.^[@ref5]^ Type II is CYB^5^R deficiency in all cells. Life expectancy is short -- most die in infancy, compared to normal life expectancy in type I. In addition to the usual symptoms caused by increased MetHb in the blood, affected infants exhibit mental retardation and developmental delay at an early age with full phenotype manifestation at 4-9 months of life.^[@ref6],[@ref7]^

Diagnosis {#sec2-1}
---------

Blood gas analysis is simple, precise and most readily available diagnostic test. During analysis, RBCs are hemolyzed and exposed to polychromatic light toward the spectrometer where different fractions of hemoglobin absorb distinct wavelengths. The corresponding fractions of wavelengths are converted to numerical values representing various hemoglobin concentrations.^[@ref8]^ P50 oxygen dissociation curve analysis is provided by most blood gas analyzers. Although very useful measurement in critically ill, P50 is unsuitable for neonates as a result of reference range absence.^[@ref9]^

Noninvasive pulse co-oximetry is another reliable tool for diagnosing dishemoglobinemias with the advantage rapid and painless determination of hemoglobin fractions, although this determination is less precise compared to blood gas analysis.^[@ref10]^

Several bedside tests were created in attempt to provide means of diagnosis when neither of abovementioned tests can be performed. Visual analysis: blood high in MetHb appears chocolate brown opposed to dark red/violet of deoxygenated blood. Comparing normal and patient's blood side by side can also be helpful. Color chart was created to aid interpretation.^[@ref11]^ Blood drop test consists of placing 1-2 drops of patient's blood on white filter paper and exposing it to atmospheric/supplemental oxygen. While venous (deoxyhemoglobin rich) blood brightens upon oxygen exposure, no change occurs in patients with methemoglobinemia. However, all bedside tests rely considerably on clinician's perception of color and therefore are prone to variable interpersonal interpretation.

Diagnosis of hereditary methemoglobinemia requires additional investigation alongside the aforementioned. CYB^5^R activity test is important to establish an accurate diagnosis. Neonates have only 50-60% of the normal adult level of CYB^5^R activity and it is not until the age of 12 months that the adult range is attained.^[@ref12]^ Observing reduced CB^5^R activity in leucocytes as well as erythrocytes confirms diagnosis of type II methemoglobinemia.^[@ref7]^ Genetic testing for type II disease should be made available to all affected families, due to high recurrence rate and poor prognosis.^[@ref5]^ Hemoglobin electrophoresis is necessary for excluding hemoglobinopathies such as hemoglobin M disease.^[@ref13]^

###### 

Capillary blood gas measurement results.

  Blood gas analyzer   ABL90 FLEX   ABL800 BASIC[\*](#tfn1){ref-type="table-fn"}           
  -------------------- ------------ ---------------------------------------------- ------- -------
  pH                   7.422        7.415                                          7.450   7.450
  pO2                  48.0         48.4                                           46.5    55.3
  pCO2                 37.7         42.2                                           38.4    31.4
  MetHb (%)            2.8          2.6                                            3.2     4.0
  BE                   0.4          1.9                                            2.6     -0.5
  Lac                  1.9          1.7                                            1.3     \-

\*Central laboratory analyzer. MetHb, methemoglobin; BE, base excess; Lac, lactate.

###### 

Clinical symptoms in relation to MetHb blood concentration.

  MetHb % of total Hb   Symptoms
  --------------------- ---------------------------------------------------------
  \<10                  Asymptomatic
  10-20                 Cyanosis
  20-40                 Headache, fatigue, weakness, tachycardia, and dizziness
  40-50                 Dyspnea and lethargy
  50-70                 Acidosis, arrhythmias, hypoxia, seizures and coma
  \>70                  Death

MetHb, methemoglobin; Hb, hemoglobin.

![Phenotypic features of the mother.](cp-9-4-1188-g001){#fig001}

![Markedly darker discoloration of blood compared with healthy controls (1, patient; 2, patient's mother; 3, 4, healthy controls).](cp-9-4-1188-g002){#fig002}

In our case primary testing of MetHb was faulty and misleading, which resulted in misdiagnosis and unnecessary interventions for the child, unwarranted separation and anxiety for the parents as well as increased length of stay associated with treatment expenses. Both blood gas analyzers used use spectrophotometry for measuring MetHb in blood, only ABL800 BASIC analysis revealed increased MetHb content. We were unable to ascertain the cause, as sampling or storing errors could not account for inaccurate readings for multiple samples taken before and after device calibration. The case highlights the importance of critical evaluation of device measurements even in tested analyzers as failing measurements or false results can occur.^[@ref14],[@ref15]^ Although our diagnosis was not complete, as Cytochrome B reductase activity was not determined, no clinical signs except of mild cyanosis, no cognitive delay in child's development at 6 months of age and otherwise healthy family phenotype suggests type 1 disease.^[@ref6]^ Early cyanosis, which improved over time without specific treatment could be explained by low CYB^5^R activity in infants at birth.^[@ref16]^ It is unlikely, that in our patients MetHb concentration would increase without external offending agents or oxidative stress, as CYB^5^R activity increases with age and reaches adult levels at the end of 1 year of life.^[@ref12]^

Management {#sec2-2}
----------

Increased MetHb concentration above 10% should be the indication for treatment of methemoglobinemia in neonates. Mainstay of therapy is IV administration of methylene blue (0.5-2mg/kg over 5 min) with or without placement in hyperbaric oxygen chamber.^[@ref17]^ Effects usually are visible within an hour, but if insufficient reduction is achieved, infusion can be repeated after 60 minutes. In neonates it is recommended to start at lower end of the dose, as it might be as effective as higher and carries lower risk of hemolysis.^[@ref18]^ If side effects (hemolytic anemia) arise or there is no effect of medical treatment, exchange blood transfusion may be recommended.^[@ref19]^

Conclusions {#sec1-4}
===========

Congenital methemoglobinemia is a rare condition, presenting with cyanosis without respiratory distress and should rouse suspicion in clinicians when more common causes are eliminated. Syndrome severity depends on percentage of MetHb in the blood and ranges from asymptomatic presentation to life threatening hypoxia, due to reduced oxygen availability to the tissues. In neonatal population, treatment should be initiated early, due to limited compensatory capabilities in the first month of life. Prognosis depends on the disease type: type I leads a normal life while most patients with type II succumb to the disease in infancy.
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